cas 7752-78-5|| where to buy 5-bromo-2-methylpyrimidine

Product Name:5-bromo-2-methylpyrimidine

IUPAC Name:5-bromo-2-methylpyrimidine

Packing Unit	Available Stock	Price($)
CM104177-100g	in stock	ůŗŹ
CM104177-250g	in stock	ǤȎů

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 7752-78-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:7752-78-5; Molecular Formula:C5H5BrN2; Melting Point:-; Smiles Code:CC1=NC=C(Br)C=N1; Density:

: Catalog Number:CM104177; Molecular Weight:173.01; Boiling Point:; MDL No:MFCD07375143; Storage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Voydeya; Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.